The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Globe Investor

News Sources

Take control of your investments with the latest investing news and analysis

Press release from PR Newswire

Hologic to Release Second Quarter Fiscal 2010 Operating Results on Monday, May 3, 2010

Thursday, April 01, 2010

Hologic to Release Second Quarter Fiscal 2010 Operating Results on Monday, May 3, 201012:07 EDT Thursday, April 01, 2010BEDFORD, Mass., April 1 /PRNewswire-FirstCall/ -- Hologic, Inc. (Hologic or the Company) (Nasdaq: HOLX), a leading developer, manufacturer and supplier of premium diagnostics, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, today announced plans to release its second quarter fiscal 2010 operating results on Monday, May�3,�2010 after market close. In conjunction with the release, management will host a conference call on Monday, May 3, 2010, at 5:00 p.m. (eastern).Interested participants may listen to the call by dialing 877-440-5803 or 719-325-4826 for international callers and referencing code 9949838 approximately 15 minutes prior to the call on May 3rd. For those unable to participate in the live broadcast, a replay will be available one hour after the call ends through Friday, May 21, 2010, at 888-203-1112 or 719-457-0820 for international callers, access code 9949838.The Company will also provide a live webcast of the call. Interested participants may access the webcast on the Company's website at www.hologic.com/investors-overview. A replay of the call will be archived on the Company's website.About Hologic, Inc. Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women. Hologic's core business units are focused on breast health, diagnostics, GYN surgical, and skeletal health. Hologic provides a comprehensive suite of technologies with products for mammography and breast biopsy, radiation treatment for early-stage breast cancer, cervical cancer screening, treatment for menorrhagia, permanent contraception, osteoporosis assessment, preterm birth risk assessment, mini C-arm for extremity imaging and molecular diagnostic products including reagents for a variety of DNA and RNA analysis applications. For more information, visit www.hologic.com.Contact:Deborah R. GordonVice President, Investor RelationsHologic, Inc.(781) 999-7716SOURCE Hologic, Inc.For further information: Deborah R. Gordon, Vice President, Investor Relations, Hologic, Inc., +1-781-999-7716